Author: Ravi Shankar

Perpetual, royalty-free, exclusive licence for DDR oncology including all future platform improvements, in exchange for C$1.0 million in Rakovina shares

VANCOUVER, British Columbia, Nov. 10, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced that it has entered into a software licence agreement (the “Licence Agreement”) with privately held Artemis Therapeutics Inc. (“Artemis”) granting Rakovina an exclusive, worldwide and perpetual licence (the “Licence”) to use Artemis.AI™, Artemis’s artificial intelligence (AI), computational chemistry and machine-learning platform, including its Deep Docking™ technology, for DNA-damage response (DDR) oncology drug discovery and development.

The Licence covers the entire DDR oncology field including the targets of Rakovina’s current programs. Rakovina pays for the Licence in two share tranches, with no cash licence fees, royalties or milestone payments, and owns the compounds it discovers.

“This exclusive license for Artemis.AI together with all future platform improvements in the field, creates a durable competitive advantage for Rakovina in the DDR oncology field,” said Kim Oishi, Chief Executive Officer of Rakovina Therapeutics. “Just as important are the people behind the platform. Dr. Cherkasov and the Artemis team, led by Frank Holler, have one of the strongest track records in AI-enabled drug discovery, and they will be working alongside Rakovina’s scientists led by Dr. Mads Daugaard. Our team has been further strengthened by the recent appointments of Dr. Ranjit Bindra, Scientific Director of the Yale Brain Tumor Center, to our Scientific Advisory Board and Professor Petra Hamerlik, Chair of Translational Neuro-Oncology at the University of Manchester and former CNS Cancer Bioscience Lead at AstraZeneca, to our Board of Directors. Combining world-class AI with deep DDR biology and rigorous experimental validation is how we intend to turn computational designs into drug candidates ready for pharmaceutical partnership.”

“The technology behind Artemis.AI has a proven record. Drug candidates identified with it have been licensed to pharmaceutical companies and advanced into clinical trials, and Dr. Cherkasov’s team has won two international CACHE drug-discovery challenges and this year completed what we believe is the first trillion-molecule virtual screen,” said Frank Holler, Executive Chairman and Chief Executive Officer of Artemis. “Our goal in every collaboration is to pair the platform with partners who bring deep knowledge of their targets and the laboratory capability to validate what the AI designs, and to share in the success of the candidates that emerge. Rakovina brings exactly that to DNA-damage response, and our option to co-develop selected candidates gives both companies a path to build value together.”

Key Terms of the Licence

Scope. Exclusive, worldwide and perpetual use of the Artemis.AI platform within DDR oncology drug discovery and development, including all updates and platform improvements and any platforms Artemis later licenses or acquires. The platform is hosted on Artemis’s servers, and up to ten hours of expert support per month are included.

Ownership and economics. Rakovina retains its existing compounds and programs, owns the compounds and data it generates with the platform, and may seek patent protection for them. No royalties or milestone payments are payable on drugs Rakovina discovers unless they are subject to a separate co-development agreement. Artemis retains ownership of the platform.

Co-development option. Artemis has a 60-day option to co-develop any platform-derived compound that Rakovina designates for development, on terms that share costs, risks and upside in proportion to each party’s contributions. Compounds Artemis declines, and programs developed without the platform, remain entirely Rakovina’s.

Exclusivity. The Licence may convert to non-exclusive if Rakovina has no active program in the field using the platform for 18 consecutive months and does not start one within 90 days after notice from Artemis.

Consideration. Rakovina will issue to Artemis common shares (“Shares”) with an aggregate deemed value of C$1,000,000 in two tranches: (i) 2,500,000 Shares at a deemed price of C$0.20 per Share, within 10 days after TSX Venture Exchange (“TSXV”) acceptance; and (ii) C$500,000 of Shares at a deemed price equal to the greater of C$0.265 and the Market Price at issuance (a maximum of 1,886,792 Shares), on the later of the first anniversary of the effective date and TSXV acceptance. The maximum of 4,386,792 Shares represents approximately 9.9% of Rakovina’s currently issued and outstanding shares. No Shares will be issued that would make Artemis a Control Person (as defined in TSXV policies) without prior shareholder approval. The Shares will be subject to a hold period of four months and one day from issuance. No finder’s fees are payable.

The Licence Agreement is effective November 9, 2026. The issuance of Shares is subject to TSXV acceptance; if acceptance is refused and cannot be obtained within 90 days, either party may terminate the Licence Agreement. The Licence does not by itself establish a co-development arrangement for any compound or ensure that drug candidates will be identified, validated or approved.

Related-Party Disclosure

The Licence is a Non-Arm’s Length Party transaction under TSXV policies because Rakovina insiders have interests in Artemis. Frank Holler, a director of Rakovina, is Executive Chairman, Chief Executive Officer and a director of Artemis. Dr. Mads Daugaard, President and Chief Scientific Officer of Rakovina, is a co-founder, director and Chief Scientific Officer of Artemis. Kim Oishi, Chief Executive Officer and a director of Rakovina, is a director of Artemis. In addition, Dr. Artem Cherkasov, co-founder, director and Chief Technology Officer of Artemis, is a member of Rakovina’s Scientific Advisory Board. Yevgeniy Meshcherekov, a director of Rakovina, is a director of Downstream Holdings Ltd., a shareholder of Artemis. Each of Mr. Holler, Dr. Daugaard, Mr. Oishi and Dr. Cherkasov is, directly or indirectly, a significant shareholder of Artemis.

Mr. Holler, Mr. Meshcherekov and Mr. Oishi declared their interests and abstained from voting on the Licence. The Licence was reviewed and approved by the Rakovina directors who are not related parties. In its review, the non-related party directors considered, among other things, a management analysis of the fair value of the Licence prepared using cost, income and market approaches, the terms of the Share consideration, the scope of the field, the co-development option and the exclusivity provisions, and concluded that the terms of the Licence are reasonable and in the best interests of Rakovina. The analysis is a management estimate and not an independent valuation or fairness opinion.

The Licence may constitute a “related party transaction” under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). Rakovina is relying on the exemptions from the formal valuation and minority shareholder approval requirements in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the transaction, exceeds 25% of Rakovina’s market capitalization. Rakovina did not file a material change report more than 21 days before entering into the Licence Agreement because the terms were not finalized until shortly before signing. The Licence remains subject to TSXV acceptance.

About the Artemis Team

Artemis is led by Executive Chairman and Chief Executive Officer Frank Holler and Co-Founder and Chief Technology Officer Dr. Artem Cherkasov. Mr. Holler is a co-founder and former President and Chief Executive Officer of ID Biomedical Corporation, which was acquired by GSK for C$1.7 billion, a founding director of Angiotech Pharmaceuticals, and a former President and Chief Executive Officer of Xenon Pharmaceuticals. Dr. Cherkasov holds a Tier 1 Canada Research Chair in Precision Cancer Drug Design, is a Professor at the University of British Columbia (UBC) and heads the Therapeutics Development Core at the Vancouver Prostate Centre. He has co-authored more than 200 research papers and 80 patent filings, and eight drug candidates from his work have been licensed to pharmaceutical companies. His team developed Deep Docking™, which has been used to screen more than 40 billion molecules and placed first in two international CACHE Challenges, for Parkinson’s disease and COVID-19. Dr. Mads Daugaard, President and Chief Scientific Officer of Rakovina, is also a Co-Founder and Chief Scientific Officer of Artemis.

Artemis’s advisory board includes Dr. Alexander Tropsha, a leading researcher in cheminformatics and predictive modelling at the UNC Eshelman School of Pharmacy and selected to receive the American Chemical Society’s 2027 Herman Skolnik Award; Dr. Poul Sorensen, Distinguished Scientist at BC Cancer and Professor of Pathology at UBC, whose discovery of the NTRK gene fusion underpinned the tumour-agnostic cancer therapy Larotrectinib; Dr. S. Larry Goldenberg, Professor of Urologic Sciences at UBC and a Member of the Order of Canada and the Order of British Columbia; and Jordan Zwick, Chief Business Officer of Mirador Therapeutics.

About Artemis Therapeutics Inc.

Artemis Therapeutics Inc. is a privately held biotechnology company developing AI-enabled computational approaches to drug discovery. Emerging from more than two decades of research in computational chemistry, molecular modelling and AI-enabled drug discovery led by Dr. Artem Cherkasov and collaborators at UBC, Artemis aims to connect computational discovery with biological validation and the advancement of promising therapeutic candidates. For more information, please visit www.artemistherapeutics.ai.

About Rakovina Therapeutics Inc.

Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI). By using AI, we can review and optimize drug candidates at a much greater pace than ever before.

The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at www.rakovinatherapeutics.com.

For Further Information Contact:

Rakovina Therapeutics Inc.
Kim Oishi
CEO
Kim.oishi@rakovinatherapeutics.com

Mark Mitchell
Communications
IR@rakovinatherapeutics.com

Artemis Therapeutics Inc.
Vanessa Ooms
Communications
Vanessa@artemistherapeutics.ai

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Notice Regarding Rakovina Therapeutics Forward-Looking Statements:

This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans,” “is expected,” “expects,” “scheduled,” “intends,” “contemplates,” “anticipates,” “believes,” “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may,” “could,” “would,” “might,” or “will” be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the biopharmaceutical industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Such risks also include, without limitation, the ability to obtain TSXV acceptance of the share issuance, the continued operation of Artemis and its continued right to license the platform, the possible conversion of the licence to non-exclusive, the performance and utility of AI-enabled discovery tools, the ability to identify and independently validate promising compounds, intellectual property considerations, and the availability of suitable co-development or commercial partners.

Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company’s most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company’s profile page at www.sedarplus.ca.

The vodka iced tea and lemonade brand is helping make the trip home a little easier with a holiday contest, covering airfare for multiple lucky drinkers, plus throwing in $100 for a bucket of Sun Cruisers once they reach their holiday destinations.

BOSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) — Getting home for the holidays is more expensive than it’s been in a decade. Sun Cruiser, the fast-growing vodka iced tea and lemonade brand made for good times, wants to make getting there a little less stressful and celebrating a little easier. 

Starting today, Sun Cruiser is launching the Cruisin’ Home Fund, a contest giving eligible drinkers the chance to have their roundtrip holiday airfare reimbursed, up to $800, plus an extra $100 to help get the holiday drinks flowing once they arrive.

The average domestic roundtrip fare for Christmas is $452, up 23% from last year*, making this the most expensive holiday travel season in a decade. And last year, one-way fares during the 10 days around Christmas ran 58% higher than a typical week in early November**. 

That’s a lot standing between you and your favorite people. So, this holiday season, Sun Cruiser is picking up the airfare for multiple lucky drinkers, helping them skip the travel stress and cruise straight into the holiday festivities waiting at home. 

How the Cruisin’ Home Fund Works

From November 10 through December 14, eligible drinkers can enter the Cruisin’ Home Fund contest at SunCruiserCruisinHomeFund.com by uploading proof of their holiday flight booking and sharing how they’ll be celebrating the holidays with Sun Cruiser for a chance to snag a portion of the Fund. 

Selected winners will receive reimbursement via Venmo for the value of their roundtrip airfare, up to $800, for eligible travel between December 18 and January 3. And because no holiday homecoming is complete without a little celebrating, each winner will also get an extra $100 to help cover the first round or two of Sun Cruisers when they reunite with friends and family. 

A Sun Cruiser for Every Reunion

Whether it’s catching up at your hometown bar, heading to a holiday party or getting the old crew back together, Sun Cruiser is ready for wherever the holidays take you.

Available in Iced Tea + Vodka styles like Classic, Peach, Raspberry and Half & Half, plus Lemonade + Vodka flavors including Classic, Pink Lemonade, Strawberry Lemonade and Blueberry Lemonade, Sun Cruiser is bubble-free with 100 calories, 1g of sugar and 4.5% ABV per 12 oz. serving.

“Getting home for the holidays should be about the people you can’t wait to see, not how much it costs to get there,” said Erica Taylor, senior brand director for Sun Cruiser. “With the Cruisin’ Home Fund, we’re helping take a little stress out of the trip so our drinkers can focus on the best part: getting home, cracking open a Sun Cruiser and spending time with their favorite people.”

Ready to cruise home for the holidays? Us, too! To enter the Cruisin’ Home Fund, visit SunCruiserCruisinHomeFund.com or to find Sun Cruiser close to you, visit DrinkSunCruiser.com/Find. And, follow along for all things Sun Cruiser on social @DrinkSunCruiser.

About Sun Cruiser

Sun Cruiser Iced Tea & Vodka is a spirits-based, ready-to-drink brand from The Boston Beer Company, made with real brewed tea, real vodka, and real lemonade. Smooth, refreshing, and bubble-free, Sun Cruiser is crafted for people who love getting outside and making the most of the sun. At 4.5% ABV, 100 calories, and just 1g of sugar per 12oz. serving, it’s easy to sip all day long. Sun Cruiser is available in Classic Iced Tea, Half and Half, Peach Iced Tea, Classic Lemonade, and more. For more information, visit drinksuncruiser.com.

About The Boston Beer Company

The Boston Beer Company, Inc. (NYSE: SAM) began in 1984 brewing Samuel Adams beer and has since grown to become one of the largest and most respected craft brewers in the United States. We consistently offer the highest-quality products to our drinkers, and we apply what we’ve learned from making great-tasting craft beer to making great-tasting and innovative “beyond beer” products. Boston Beer Company has pioneered not only craft beer but also hard cider, hard seltzer, and hard tea. Our core brands include household names like Angry Orchard Hard Cider, Dogfish Head, Samuel Adams, Sun Cruiser, Truly Hard Seltzer, and Twisted Tea Hard Iced Tea. For more information, please visit https://www.bostonbeer.com/.

*Hopper, 2026 Holiday Travel Index (published September 25, 2026), media.hopper.com/research/2026-holiday-travel-index. 

**Upgraded Points, “The Best Day of the Week To Fly During the Holidays” (2025 data study), upgradedpoints.com/news/best-day-fly-during-holidays.

Attachment

• Sun Cruiser Cruisin’ Home Fund

CONTACT: Christina Boyadjian
Sun Cruiser Iced Tea & Vodka
GolinKetchumSunCruiser@omnicompr.com

• Building on a 25-year partnership, AvePoint combines AI innovation with the governance, resilience, and control required for enterprise adoption in collaboration with Microsoft
• AvePoint solutions extend AI trust across data, infrastructure, and agents as adoption of Microsoft Copilot, Agent 365, Copilot Studio, and Microsoft Foundry accelerates

JERSEY CITY, N.J., Nov. 10, 2026 (GLOBE NEWSWIRE) — AvePoint (Nasdaq: AVPT, SGX: AVP), the AI Trust Company, today announced an expanded strategic partnership with Microsoft to help organizations deploy, govern, secure, and optimize AI across their enterprises. Building on nearly 25 years of collaboration, and a track record that includes six global Microsoft Partner of the Year awards, the next phase of this relationship reflects a shared commitment and increased investment in supporting organizations with the governance, security, resilience, and operational controls needed to unlock AI’s full business value.

As organizations accelerate adoption of Microsoft Copilot, Agent 365, Copilot Studio, Microsoft Foundry, Microsoft 365, and Microsoft Azure, many face a growing challenge: how to maintain visibility, control, and recoverability across an increasingly complex AI estate. AvePoint’s 2026 State of AI Report found that nearly 9 in 10 organizations delayed AI initiatives due to data security and management concerns, underscoring a broader reality that AI adoption is advancing faster than many organizations can govern it. As organizations move from experimentation to enterprise-scale AI deployment, success increasingly depends on combining leading AI platforms with the governance, security, resilience, and operational expertise needed to deploy AI with confidence.

“For a quarter century, AvePoint has empowered organizations to realize the value of digital transformation,” said Dr. Tianyi Jiang (TJ), Co-Founder and Chief Executive Officer, AvePoint. “Today, AI represents the next major technology shift. Through our expanded strategic partnership with Microsoft, we’re helping organizations establish the trust, governance, and operational foundations needed to confidently deploy AI at scale. Together, we’re enabling customers to move faster while maintaining control over the data, agents, and systems powering their AI initiatives.”

Expanding AI Trust

AvePoint will continue serving as Customer Zero for AI transformation, using its own AI deployment experiences to inform product innovation and best practices for customers. Building on its successful adoption of Microsoft Copilot across its global workforce, AvePoint is deepening its investment in Microsoft by expanding access to Microsoft 365 E7, empowering employees with advanced AI and agent capabilities that help them work smarter, move faster, and drive greater operational efficiency. AvePoint’s internal adoption of Microsoft technologies generates practical insights that continue to inform the development of AgentPulse. These experiences help shape AvePoint’s approach to applying governance workflows across agents and other AI assets, with an emphasis on business context and accountability.

Driving Customer Outcomes Through Joint Innovation and Go-to-Market Collaboration

The expanded strategic partnership builds on AvePoint’s continued innovation across the Microsoft Cloud. As a Microsoft launch partner for Microsoft 365 Backup Storage, AvePoint introduced Cloud Backup Express to accelerate backup and recovery for Microsoft 365 data and has since expanded its capabilities to support prioritized recovery of critical Microsoft 365 workloads, identities, and infrastructure. As a result of deeper integration with Microsoft and the need to recover as quickly as possible from incidents, Cloud Backup Express customers have increased 45x in 2026 year to date. Additionally, AvePoint allows organizations to move beyond AI experimentation to operationalized AI with Microsoft. Microsoft Copilot, Copilot Studio, and Microsoft Foundry support AI innovation.

Microsoft Agent 365 provides a common control plane for managing agents across supported platforms, with capabilities spanning governance, visibility, resilience, and cost optimization. AvePoint’s AgentPulse is designed to complement this portfolio with governance workflows spanning agents and other AI assets. By mapping agents to business use cases, departments, and accountable owners, these workflows help organizations bring business context to governance decisions and direct attestations and remediation to the appropriate business teams. With nearly half of employees today relying on AI agents on a daily or weekly basis, this combined approach enables customers to accelerate adoption while maintaining the oversight, accountability, and business controls required to evolve into AI-powered Frontier Firms without sacrificing governance, security, or resilience.

According to Nabil Aitoumeziane, President of FSi Strategies, a customer-centric Microsoft Solutions Partner delivering enterprise-class managed IT and professional services, “A lot of organizations spent the last year getting AI-ready. Now the conversation is shifting toward execution. That’s where governance becomes critical, and where AvePoint has been a key partner for us and our customers.”

“Realizing AI’s business value at scale requires organizations to pair innovation with security, governance, and accountability,” said Edwin Vargas, Managing Director – AI Business Solutions and Security partnerships, Microsoft. “Our strategic partnership with AvePoint supports this approach by bringing together Microsoft’s AI and security capabilities with AvePoint’s focus on data governance and business-context-driven workflows, helping customers adopt AI with confidence and connect oversight to the teams putting it to work.”

Continuing Innovation for Trusted AI

As organizations move deeper into enterprise-scale AI, the next phase of the AvePoint and Microsoft partnership is focused on helping them trust their AI so they can scale innovation without scaling risk. Gartner cited AvePoint in the first ever Gartner® Magic Quadrant™ for AI Agent Management Platforms and as a representative vendor for organizations looking to secure and govern an AI native workplace, manage storage costs in Microsoft 365, complement native governance capabilities in Microsoft Purview, and mitigate the risks of agent sprawl in enterprise applications. Leading up to Microsoft Ignite in November, AvePoint will continue evolving its data resilience and governance solutions to ensure organizations are maximizing their AI investments.

To see these updates in action, please visit AvePoint at Microsoft Ignite at Booth 5535 November 17 – 20 in San Francisco, CA.

About AvePoint

AvePoint is the AI Trust Company. AvePoint helps more than 28,000 organizations and 6,000 channel partners govern, secure, and scale AI with trust: making data AI-ready, governing every agent across its lifecycle, and keeping the business resilient across every cloud they run on. To learn more, visit www.avepoint.com.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and other federal securities laws including statements regarding the future performance of and market opportunities for AvePoint. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: changes in the competitive and regulated industries in which AvePoint operates, variations in operating performance across competitors, changes in laws and regulations affecting AvePoint’s business and changes in AvePoint’s ability to implement business plans, forecasts, and ability to identify and realize additional opportunities, and the risk of downturns in the market and the technology industry. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of AvePoint’s most recent Annual Report on Form 10-K. Copies of this and other documents filed by AvePoint from time to time are available on the SEC’s website, www.sec.gov. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and AvePoint does not assume any obligation and does not intend to update or revise these forward-looking statements after the date of this release, whether as a result of new information, future events, or otherwise, except as required by law. AvePoint does not give any assurance that it will achieve its expectations. Unless the context otherwise indicates, references in this press release to the terms “AvePoint,” “the Company,” “we,” “our” and “us” refer to AvePoint, Inc. and its subsidiaries.

Disclosure Information
AvePoint uses the https://www.avepoint.com/ir website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Investor Contact
AvePoint
Jamie Arestia
ir@avepoint.com
(551) 220-5654

Media Contact
AvePoint
Nicole Caci
pr@avepoint.com
(201) 201-8143

NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) — IBEX Limited (NASDAQ: IBEX), a global leader in outsourced business services and AI-powered customer experience solutions, today announced that CEO Bob Dechant and CFO Taylor Greenwald will present at the RBC 2026 Global TIMT (Technology, Internet, Media and Telecommunications) Conference in New York City on Tuesday, November 17, 2026.

In addition to one-on-one investor meetings throughout the day, Dechant and Greenwald will present at 9:20 a.m. ET, focusing on ibex’s business outlook and answering investor questions.

A live webcast of the presentation will be available here and will be posted on ibex’s investor relations site following the event.

For more information about the RBC Capital Markets 2026 Global Industrials Conference or to schedule a meeting with management, please contact IBEX@gateway-grp.com.

About ibex
ibex is a global leader in outsourced business services and AI-powered customer experience solutions, enabling the world’s best brands to deliver truly differentiated experiences for their customers. Leveraging a global team of more than 40,000 human CX experts – powered by the best AI technology, decades of CX innovation, and deep business insights – ibex engineers seamless, end-to-end customer journeys from AI agents to human agents at scale across retail, e-commerce, healthcare, fintech, utilities, technology, logistics, and more. Discover more at ibex.co and connect with us on LinkedIn. 

Investor Contact: 
Tom Colton and Greg Bradbury
Gateway Group, Inc.
949-574-3860
IBEX@gateway-grp.com

Media Contact:  
Dan Burris
ibex
daniel.burris@ibex.co

NEW CANAAN, Conn., Nov. 10, 2026 (GLOBE NEWSWIRE) — NewLake Capital Partners, Inc. (OTCQX: NLCP) (“NewLake” or the “Company”), a leading provider of real estate capital to state-licensed cannabis operators, today announced that President and Chief Executive Officer, Anthony Coniglio, will participate as a featured speaker at the IgniteIt Cannabis Capital and Policy Summit 2026, where he will join an industry panel examining the evolving cannabis lending landscape, including shifting lender requirements and key considerations for businesses seeking to raise capital.

IgniteIt Cannabis Capital and Policy Summit 2026
Location: Grand Hyatt, Washington, D.C.
Moderator: Jeanne Sullivan, Chief Investment Officer at Arcview Ventures
Panel Title: Debt Isn’t What It Used to Be
Panel Day and Time: Wednesday, November 18^th at 1:50 p.m. ET

To schedule a one-on-one meeting with NewLake’s management team, please email KCSA Strategic Communications at NewLake@KCSA.com.

About NewLake Capital Partners, Inc.
NewLake Capital Partners, Inc. is an internally-managed real estate investment trust that provides real estate capital to state-licensed cannabis operators through sale-leaseback transactions and third-party purchases and funding for build-to-suit projects. NewLake owns a portfolio of 37 properties, including 15 cultivation facilities and 22 dispensaries, primarily leased to single tenants under triple-net lease agreements. For more information, please visit www.newlake.com.

Contact Information:
Lisa Meyer
Chief Financial Officer, Treasurer and Secretary
NewLake Capital Partners, Inc.
lmeyer@newlake.com

Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
NewLake@KCSA.com
PH: (212) 896-1254

Media Contact:
Ellen Mellody
KCSA Strategic Communications
EMellody@KCSA.com
PH: (570) 209-2947

Third Quarter Net Sales Increased by 12.3% to $16.6 Million, from $14.8 Million for the Third Quarter of 2025 

Third Quarter Net Income Increased by 97.2% to $1.9 Million from $1.0 Million in the Prior Year Period

• Net sales for the third quarter of 2026 were $16.6 million, up 12.3%, compared to $14.8 million for the third quarter of 2025 
  • Building Supply segment sales increased by $157,000, or 1.7%, to $9.4 million, compared to $9.3 million for the three months ended September 30, 2025
  • Disposable Protective Apparel segment sales increased by $1.7 million, or 30.2%, to $7.2 million, compared to $5.5 million for the same period of 2025
• Net income for the third quarter of 2026 was $1.9 million, or $0.19 per diluted share, compared to $976,000, or $0.09 per diluted share, for the third quarter of 2025
• Cash of $25.5 million and working capital of $52.1 million, with no debt, as of September 30, 2026

NOGALES, Ariz., Nov. 10, 2026 (GLOBE NEWSWIRE) — Alpha Pro Tech, Ltd. (NYSE American: APT), a leading manufacturer of products designed to protect people, products and environments, including disposable protective apparel and building products, today announced financial results for the three month period ended September 30, 2026.

Lloyd Hoffman, President and Chief Executive Officer of Alpha Pro Tech, commented, “The housing market continued to show weakness in the third quarter of 2026, as single-family housing starts declined by 1.6% compared to the corresponding period in 2025. However, this market decline in the third quarter of 2026 represents an improvement from the decline in the prior quarter. During the third quarter of 2026, we again outperformed the market, as sales of our core building products (housewrap and synthetic roof underlayment), increased by 5.2% compared to the same period of 2025, driven primarily by a 13.1% increase in housewrap sales. In the third quarter of 2026, our synthetic roof underlayment sales decreased by 6.3% compared to the third quarter of 2025, outperforming the overall market, as the Asphalt Roofing Manufacturers Association (“ARMA”) reported a steeper 13.0% decline in industry shipments.

Sales of other woven material were down 22.0% in the third quarter of 2026 compared to the same period of 2025, primarily due to timing of orders, but year to date sales for the product line were basically flat compared to the prior year period.

The building industry outlook for the remainder of 2026 reflects a soft but generally stable market, rather than a meaningful rebound. A modest increase in single-family housing starts is expected in 2027, assuming economic and financing conditions improve. The Company plans on expanding our housewrap and synthetic roof underlayment market product offerings in 2027, to enhance our competitive position and support long-term growth. Management remains focused on growth in the Building Supply segment and has recently expanded its sales team; however, uncertainty related to the factors described above remain.”

Mr. Hoffman continued, “Sales of disposable protective garments, which comprised 90% of the segment sales, increased by $1.5 million or 30.6% in the third quarter of 2026, compared to the same period of 2025. The sales increase was primarily due to improved sales across our distribution network comprised of our large international channel partner and national and regional distributors. In addition, a considerable portion of the increase was attributable to higher selling prices compared to the third quarter of 2025. The disposable protective garments product line continues to demonstrate positive momentum, with most major categories performing well ahead of the third quarter of 2025. Sales of shoe covers, lab coats and frocks, gowns, and bouffant caps, all contributed to this improved performance. The breadth of growth across these product categories is encouraging and provides an opportunity to further expand customer relationships and capture incremental business. As we enter the final quarter of 2026, our focus is on building upon this broader-based improvement, deepening customer relationships, and identifying additional opportunities to expand sales across the portfolio in 2027.

Sales of our face mask and face shield products in the third quarter of 2026, which comprise the remaining 10% of the segment sales, were up by $141,000, or 25.9%, compared to the same period of 2025. The face mask and face shield product lines are showing encouraging improvement, with both face mask and face shields posting solid gains over the prior year period. Management hopes to continue to build on this progress through focused customer engagement, targeted promotional programs, and the pursuit of new business opportunities to sustain growth and strengthen our position in these markets.”

2026 Third Quarter Financial Results:

Consolidated sales for the three months ended September 30, 2026, increased to $16.6 million from $14.8 million for the three months ended September 30, 2025, representing an increase of $1.8 million, or 12.3%. This increase consisted of increased sales in the Building Supply segment of $157,000 and increased sales in the Disposable Protective Apparel segment of $1.7 million.

Building Supply segment sales for the three months ended September 30, 2026, increased by $157,000, or 1.7%, to $9.4 million, compared to $9.3 million for the three months ended September 30, 2025. The Building Supply segment sales increase during the three months ended September 30, 2026, was primarily due to a 13.1% increase in sales of housewrap, partially offset by a 6.3% decrease in sales of synthetic roof underlayment, and a 22.0% decrease in sales of other woven material as compared to the same period of 2025.

Disposable Protective Apparel segment sales for the three months ended September 30, 2026, were $7.2 million, compared to $5.5 million for the same period in 2025, reflecting an increase of $1.7 million, or 30.2%. The segment experienced strong underlying sales growth during the quarter. The sales increase was primarily due to improved sales across our distribution network comprised of our large international channel partner and national and regional distributors. In addition, a considerable portion of the increased sales was attributable to higher selling prices compared to the third quarter of 2025.

Gross Profit
Gross profit increased by $1.1 million, or 18.2%, to $6.9 million for the three months ended September 30, 2026, from $5.9 million for the three months ended September 30, 2025. The gross profit margin was 41.8% for the three months ended September 30, 2026, compared to 39.7% for the three months ended September 30, 2025.

Gross profit margin for the third quarter of 2026 improved compared to the prior year period, primarily reflecting the rescission in late February 2026 of the 50% IEEPA (International Emergency Economic Powers Act) tariffs on goods from India, following a U.S. Supreme Court decision invalidating the use of IEEPA to authorize such tariffs. However, the U.S. Government subsequently announced a new 10% tariff under Section 122 of the Trade Act of 1974. Accordingly, the Company continues to incur tariff costs, although at a lower rate.

The net change in gross profit for the three months ended September 30, 2026 due to the IEEPA tariff refund recognized was $70,000, which was due to lower cost of goods sold.  

Net Income
Net income for the three months ended September 30, 2026, was $1.9 million, compared to net income of $976,000 for the same period of 2025, representing an increase of $949,000, or 97.2%. The net income increase between the three months ended September 30, 2026 and the same period of 2025 was due to an increase in income before provision for income taxes of $1.2 million, partially offset by an increase in provision for income taxes of $288,000. Net income as a percentage of net sales was 11.6% for the three months ended September 30, 2026, compared to 6.6% for the same period of 2025. Basic and diluted earnings per common share for the three months ended September 30, 2026 and 2025, were $0.19 and $0.09, respectively.

The net change in net income for the third quarter of 2026 due to the IEEPA tariff refund was $124,000.

Balance Sheet
As of September 30, 2026, the Company had cash of $25.5 million compared to $17.0 million as of December 31, 2025. Working capital totaled $52.1 million and the Company’s current ratio was 9:1, compared to a current ratio of 13:1 as of December 31, 2025.

Colleen McDonald, Chief Financial Officer, commented, “As of September 30, 2026, we had $914,000 available for additional stock purchases under our stock repurchase program. During the nine months ended September 30, 2026, we repurchased 97,982 shares of common stock at a cost of $483,000. As of September 30, 2026, the company has repurchased a total of 22.0 million shares of common stock at a cost of approximately $58.6 million through our repurchase program. We retire all stock upon repurchase and future repurchases are expected to be funded from cash on hand and cash flows from operating activities.”

About Alpha Pro Tech, Ltd.
Alpha Pro Tech, Ltd. is the parent company of Alpha Pro Tech, Inc. and Alpha ProTech Engineered Products, Inc. Alpha Pro Tech, Inc. develops, manufactures and markets innovative disposable and limited-use protective apparel products for the industrial, clean room, medical and dental markets. Alpha ProTech Engineered Products, Inc. manufactures and markets a line of construction weatherization products, including building wrap and roof underlayment. The Company has manufacturing facilities in Nogales, Arizona, Valdosta, Georgia; and a joint venture in India. For more information and copies of all news releases and financials, visit Alpha Pro Tech’s website at http://www.alphaprotech.com.

Certain statements made in this press release constitute “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statement that may predict, forecast, indicate or imply future results, performance or achievements instead of historical facts and may be identified generally by the use of forward-looking terminology and words such as “expects,” “anticipates,” “estimates,” “believes,” “predicts,” “intends,” “plans,” “potentially,” “may,” “continue,” “should,” “will” and words of similar meaning. Without limiting the generality of the preceding statement, all statements in this press release relating to estimated and projected earnings, expectations regarding order volume, timing of fulfillment of orders, production capacity and our plans to ramp up production and expand capacity, product demand, availability of raw materials and supply chain access, margins, costs, expenditures, cash flows, sources of capital, growth rates and future financial and operating results are forward-looking statements. We caution investors that any such forward-looking statements are only estimates based on current information and involve risks and uncertainties that may cause actual results to differ materially from the results contained in the forward-looking statements. We cannot give assurances that any such statements will prove to be correct. Factors that could cause actual results to differ materially from those estimated by us include the risks, uncertainties and assumptions described from time to time in our public releases and reports filed with the Securities and Exchange Commission, including, but not limited to, our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Specifically, these factors include, but are not limited to, our exposure to foreign currency exchange risks related to our unconsolidated affiliate operations in India; potential failure to remediate the material weakness in our internal controls; our partnership with a joint venture partner; the loss of any major customer or a reduction in order volume by our customers; the inability of our suppliers and contractors to meet our requirements; potential challenges related to international manufacturing; the inability to protect our intellectual property; competition in our industry; customer preferences; the timing and market acceptance of new product offerings; changes in global economic conditions; security breaches or disruptions to the information technology infrastructure; risks related to climate change and natural disasters or other events beyond our control; the effects of tariff policies, ongoing trade disputes and related litigation, including related to tariff refunds, and potential countermeasures; potential liabilities from environmental laws and regulations; uncertainties with respect to the development, deployment, and use of artificial intelligence; the impact of legal and regulatory proceedings or compliance challenges; and volatility in our common stock price and our investments. We also caution investors that the forward-looking information described herein represents our outlook only as of this date, and we undertake no obligation to update or revise any forward-looking statements to reflect events or developments after the date of this press release. Given these uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Condensed Consolidated Balance Sheets (Unaudited)
	September 30,				December 31,
	2026				2025 (1)
Assets
Current assets:
Cash and cash equivalents	$	25,546,000			$	16,988,000
Accounts receivable, net		7,806,000				6,936,000
Accounts receivable, related party		1,635,000				1,202,000
Inventories, net		17,854,000				23,598,000
Prepaid expenses		5,975,000				3,796,000
Total current assets		58,816,000				52,520,000
Property and equipment, net		7,832,000				8,234,000
Goodwill		55,000				55,000
Right-of-use assets		7,230,000				7,775,000
Equity investment in unconsolidated affiliate		5,807,000				5,548,000
Total assets	$	79,740,000			$	74,132,000
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable	$	2,168,000			$	2,005,000
Accrued liabilities		3,528,000				1,088,000
Lease liabilities		1,054,000				965,000
Total current liabilities		6,750,000				4,058,000
Lease liabilities, net of current portion		6,302,000				6,917,000
Deferred income tax liabilities, net		679,000				679,000
Total liabilities		13,731,000				11,654,000
Commitments and contingencies
Shareholders’ equity:
Common stock, $.01 par value: 50,000,000 shares authorized;
10,177,759 and 10,131,565 shares outstanding as of
September 30, 2026 and December 31, 2025, respectively		101,000				101,000
Additional paid-in capital		15,592,000				15,828,000
Retained earnings		52,622,000				48,496,000
Accumulated other comprehensive loss		(2,306,000	)			(1,947,000	)
Total shareholders’ equity		66,009,000				62,478,000
Total liabilities and shareholders’ equity	$	79,740,000			$	74,132,000

_{⁽¹⁾ The condensed consolidated balance sheet as of December 31, 2025, has been prepared using information from the audited consolidated balance sheet as of that date.}

Condensed Consolidated Statements of Income (Unaudited)
		For the Three Months Ended						For the Nine Months Ended
		September 30,						September 30,
		2026			2025			2026			2025
Net sales		$	16,604,000		$	14,785,000		$	49,863,000		$	45,279,000
Cost of goods sold, excluding depreciation
and amortization			9,667,000			8,917,000			30,432,000			27,888,000
Gross profit			6,937,000			5,868,000			19,431,000			17,391,000
Operating expenses:
Selling, general and administrative			4,741,000			4,568,000			14,125,000			13,818,000
Depreciation and amortization			226,000			203,000			744,000			686,000
Total operating expenses			4,967,000			4,771,000			14,869,000	–		14,504,000
Income from operations			1,970,000			1,097,000			4,562,000			2,887,000
Other income:
Equity in income of unconsolidated affiliate			254,000			27,000			618,000			305,000
Interest income, net			306,000			169,000			619,000			484,000
Total other income			560,000			196,000			1,237,000			789,000
Income before provision for income taxes			2,530,000			1,293,000			5,799,000			3,676,000
Provision for income taxes			605,000			317,000			1,346,000			843,000
Net income		$	1,925,000		$	976,000		$	4,453,000		$	2,833,000
Basic earnings per common share		$	0.19		$	0.09		$	0.44		$	0.27
Diluted earnings per common share		$	0.19		$	0.09		$	0.43		$	0.27
Basic weighted average common shares outstanding			10,105,777			10,354,289			10,119,275			10,525,957
Diluted weighted average common shares outstanding			10,371,760			10,485,088			10,363,605			10,642,957

Company Contact:	Investor Relations Contact:
Alpha Pro Tech, Ltd.	HIR Holdings
Donna Millar	Cameron Donahue
905-479-0654	651-707-3532
e-mail: ir@alphaprotech.com	e-mail: cameron@hirholdings.com

New customer experiences from Towne Millwork and E.M. Duggan show how AI is helping contractors improve estimating, streamline workflows and increase productivity.

PASADENA, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) — Bluebeam a leading developer of solutions and services for architecture, engineering, and construction (AEC) professionals worldwide and part of the Nemetschek Group, today highlighted how specialty contractors and construction firms are leveraging AI capabilities in Bluebeam Revu to transform everyday project workflows. Available through Bluebeam’s top-tier Max plan, these full-suite AI tools are helping contractors manage the bottlenecks that are being felt industry-wide. The customer stories come as Bluebeam’s latest industry research found that only 28% of AEC firms have moved AI into production despite reporting significant business benefits. 

“Contractors don’t need entirely new processes to realize value from AI,” said Usman Shuja, CEO of Bluebeam & Executive Board Member, Nemetschek Group. “The most successful applications of AI enhance the workflows teams already trust. By embedding AI directly into the trusted tools teams rely on every day, we’re empowering contractors to pair their uniquely deep, hands-on knowledge with the digital fluency critical to the future of the industry. This approach amplifies AEC professionals’ expertise, making institutional knowledge instantly accessible, cutting down on document complexity and helping teams build a smarter future from the ground up.”  

Towne Millwork Finds Everyday Efficiency Gains with Max 

For Doug McLean, senior estimator at Towne Millwork Ltd., the value of upgrading to Max became apparent almost immediately. After participating in the beta program, the team adopted the platform to streamline revisions, improve consistency across takeoffs and make project information easier to access during estimating. 

Architectural millwork projects often undergo material and finish changes throughout the estimating process, creating additional work as teams update markups and takeoffs. Max has helped Towne Millwork simplify those revisions, improve consistency across estimating workflows and reduce the effort required to locate and validate project information. 

“When the beta ended, we really missed the “Convert To” function, so as soon as we could, I insisted my team upgrade our Bluebeam subscription to Max,” said Doug McLean, senior estimator at Towne Millwork Ltd. “Estimating architectural millwork involves endless revisions that can easily derail a schedule. When other estimators ask me whether it’s worth it, I tell them Bluebeam Max pays for itself every day.”   

Following deployment, Towne Millwork expanded access to Bluebeam’s AI features across its estimating team, using the platform to simplify revisions, improve takeoff workflows and reduce the time spent locating critical project information. 

E.M. Duggan Integrates AI into Estimating and Preconstruction Workflows 

Bluebeam’s AI capabilities are helping E.M. Duggan to enhance and expedite its estimating and preconstruction workflows, enabling teams to analyze project information more efficiently and validate work with greater confidence. 

Because Bluebeam was already deeply embedded within the organization’s workflows, E.M. Duggan was able to introduce AI without disrupting established processes. The company has since expanded use among estimators and project managers as teams identify new ways to accelerate project planning and estimating activities. 

“Everybody in this industry already uses Bluebeam. What’s different with Max is that it gives us an AI assistant directly in the estimating workflow instead of requiring a separate tool or additional workflow,” said Jeff Elwell, CTO of E.M. Duggan. “Our estimators use it to check their baseline numbers and catch things that used to slip through the cracks. It cuts out a lot of manual counting and double-checking, and we’re getting to a solid estimate we can trust a lot faster

Following the initial rollout, E.M. Duggan expanded use of Max across project managers and estimators, applying AI-powered capabilities to support estimating workflows and make project expertise more accessible across teams. 

In an industry where 93% of firms prioritize digital expertise but many remain stuck in the pilot phase, early adopters are setting a new standard for operational efficiency.  The success of Towne Millwork and E.M. Duggan show how contractors are using AI to eliminate manual overhead, accelerate estimating and unlock immediate ROI, proving that practical AI is a competitive necessity.  

Bluebeam Max, which includes access to Bluebeam Revu’s full suite of AI features, is available globally. Existing Bluebeam users and new customers can explore AI capabilities, start a free trial, or learn more about Bluebeam subscription tiers at www.bluebeam.com/bluebeam-max.  

To keep up with the latest on what is available to Bluebeam users today, visit www.bluebeam.com/whats-new.

 

About Bluebeam 

Bluebeam is the leading provider of digital productivity and collaboration solutions for industries that design and build our world. Since 2002, Bluebeam has made desktop, mobile and cloud-based solutions for paperless workflows that improve project communication and streamline processes across the entire project lifecycle. Trusted by over 4 million users in more than 160 countries, Bluebeam’s solutions empower professionals to make their mark, adapt to change, and deliver projects successfully. Headquartered in Pasadena, CA, Bluebeam has offices globally and is part of the Nemetschek Group.    

CONTACT: Nicole Worley
Bluebeam
nworley@bluebeam.com

SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that it will host a conference call and webcast at 4:30 PM Eastern Time on Monday, November 16, 2026, to review its financial results for the quarter ended September 30, 2026 and to provide a company update.

To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 5942376. The live webcast can be accessed under “Presentations, Events & Webcasts” in the Investors section of the company’s website at ir.darebioscience.com. Please log in approximately 5-10 minutes prior to the call to register and to download and install any necessary software. The webcast will be archived in the same section of the company’s website and available for replay for 90 days.

ABOUT DARÉ BIOSCIENCE, INC.

Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Daré Bioscience advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré Bioscience is working to close critical gaps in care using science that serves her needs. For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Daré Bioscience is working to change that. Learn more at darebioscience.com.

Contact:
Daré Bioscience Investor Relations
innovations@darebioscience.com

Source: Daré Bioscience, Inc.

Strong sales performance throughout 2026 reflects growing demand across marine and data center applications

BALLERUP, Denmark, Nov. 10, 2026 (GLOBE NEWSWIRE) — LiqTech International, Inc. (Nasdaq: LIQT) (“LiqTech” or the “Company”), a clean technology company specializing in advanced filtration technologies, today announced new orders from established customers in its Diesel Particulate Filter (DPF) business, bringing its DPF order backlog to its highest level in years.

The new orders reflect continued demand for LiqTech’s advanced filtration solutions and expanding applications across marine markets, including shipyards, and the data center sector.

LiqTech’s DPF business has demonstrated consistently strong commercial performance throughout 2026, with sales exceeding budget in each of the first three quarters. This positive momentum continued into the fourth quarter. Sales order from January 1 to November 1 has an increase of 30% compared with the same period in 2025.

The continued order activity highlights the strength of LiqTech’s long-standing customer relationships and the growing opportunities to expand its DPF technology into additional applications and end markets.

As part of its strategy to accelerate growth within its established businesses, LiqTech has intensified direct customer engagement, including increased face-to-face meetings and closer collaboration with key accounts. These initiatives are focused on identifying emerging filtration requirements, developing new applications, and converting commercial opportunities into additional orders.

“These new orders and our consistently strong sales performance throughout 2026 demonstrate the resilience and growth potential of our DPF business,” said Fei Chen, Chief Executive Officer of LiqTech International. “With our order backlog reaching its highest level in years, we are encouraged by the continued demand from established customers and the expanding applications of our technology.

“Our silicon carbide and cordierite filtration solutions are designed to meet demanding diesel exhaust emission control requirements across a broad range of applications. By strengthening customer engagement and leveraging our proven technology portfolio, we see attractive opportunities to further expand our presence in marine, data centers, and other industrial markets.”

About LiqTech International Inc.

LiqTech International, Inc., a Nevada corporation, is a high-tech filtration technology company that provides state-of-the-art ceramic silicon carbide filtration technologies for gas and liquid purification. LiqTech’s silicon carbide membranes are designed to be used in the most challenging purification applications, and its silicon carbide filters are used to control diesel exhaust soot emissions. Using nanotechnology, LiqTech develops products using its proprietary silicon carbide technology, resulting in a wide range of component membranes, membrane systems, and filters for both microfiltration and ultrafiltration applications. By incorporating LiqTech’s SiC liquid membrane technology with the Company´s extensive systems design experience and capabilities, LiqTech offers unique, modular designed filtration solutions for the most difficult water purification applications.

For more information, please visit www.liqtech.com 

Follow LiqTech on LinkedIn: http://www.linkedin.com/company/liqtech-international 

Follow LiqTech on X: https://x.com/LiqTech

Forward–Looking Statement

This press release contains “forward-looking statements.”  Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements.  Readers are urged to carefully review and consider the various disclosures made by us in the reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation, and cash flows.  If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.  Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.

We assume no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

LiqTech Company Contact                                         
Susan Keegan Elleskov
Head of Marketing
LiqTech International, Inc.
Phone: +45 31315941
www.liqtech.com

LiqTech Investor Contact                                         
Robert Blum
Lytham Partners, LLC                                 
Phone: 602-889-9700
liqt@lythampartners.com

Long-term Gateway agreement supports Kratos’ first offshore mission in 2027 and multiple planned launches in subsequent years

Gateway™ offshore launch platform

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6bce8d6c-8a04-4d2e-bad7-c7d636371732

SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS), a technology company in defense, national security, and global markets, today announced a long-term agreement with Seagate Space for use of the company’s initial Gateway^™ offshore launch platform. The agreement supports Kratos’ planned first mission from the platform in 2027, with multiple additional launches anticipated in subsequent years.

The partnership aligns Kratos’ mission of being first to market and proven record of delivering real, mission-relevant products and systems, including hypersonic test and other vehicles, rocket systems, propulsion technologies, target vehicles, and launch services, with Seagate Space’s modular, mobile offshore platform infrastructure. The Gateway series vessels are designed to provide flexible sea-based platforms to complement traditional land-based launch sites and test ranges.

The announcement coincides with Seagate Space’s execution of its first Gateway platform construction contract, advancing into physical construction and toward future operational readiness.

“Kratos’ agreement with Seagate Space creates an important new pathway for supporting our customers’ evolving launch and test requirements,” said Dave Carter, President of Kratos Defense & Rocket Support Services. “We are focused on delivering affordable, responsive, and mission-critical solutions. Gateway has the potential to provide our customers with additional launch flexibility, expanded operating locations, and responsive access to mission-relevant test environments.”

Seagate Space’s Gateway platform is being developed as a modular and mobile offshore system to support government and commercial launch, testing, and recovery missions. Its maritime mobility can provide mission planners with added flexibility in launch geometry, range access, and scheduling while reducing dependence on fixed terrestrial infrastructure.

Kratos plans to use the Gateway platform initially in support of defense-related launch and target missions. The companies expect their collaboration to establish a foundation for expanded offshore mission operations as demand grows for hypersonic testing, ballistic-missile targets, responsive launch capabilities, and other national security relevant missions.

“From the beginning, our vision has been to make access to space as open as the ocean itself,” said Sean Fortener, President, Chief Operating Officer and Co-Founder of Seagate Space. “Partnering with Kratos and moving our first Gateway platform into construction represents a major step towards making that vision a reality. Kratos brings real mission requirements and decades of defense experience, and Seagate Space is bringing the maritime infrastructure to support them. With our first build contract signed, we are putting steel behind the vision and moving closer to delivering a capability the industry needs.”

Kratos has internally invested in rapidly developing and fielding affordable systems for demanding national security missions. Kratos’ approach is based on the belief that affordability is a technology: designing proven, leading-edge products and systems from the outset for rapid production, operational deployment, and scalable manufacturing.

“Kratos is committed to being first to market with affordable, relevant, mission-focused technology and systems that address the urgent requirements of the United States and its allies,” said Eric DeMarco, Kratos President and CEO. “This partnership with Seagate Space supports our mission and strategy, by creating an additional option for our customers to conduct critical launch and test missions. Sea-based launch infrastructure can provide flexibility, responsiveness, and operational choice—capabilities increasingly important to national security missions.”

The companies will continue to advance Gateway through construction, integration, and operational-readiness activities in preparation for Kratos’ first planned mission in 2027.

About Kratos Defense & Security Solutions, Inc.
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low cost future manufacturing which is a value add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com and follow Kratos on LinkedIn and X.

About Seagate Space
Seagate Space is space’s maritime partner: reinventing offshore launch, optimizing recovery, and innovating for emerging logistics needs. The company’s cutting-edge designs enable rapid, cost-effective development of offshore launch assets that can operate without the constraints of traditional land-based ranges. Seagate Space is a spARK Labs by ARK Invest member company headquarter in the St. Petersburg, Florida. Learn more at seagatespace.com and follow us on LinkedIn.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 28, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Cantrell
claire.cantrell@kratosdefense.com

Investor Information:
877-934-4687
investor@kratosdefense.com